15 May 2023
LungLife AI, Inc.
("LungLife" or the "Company")
Block Listing Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
| Name of applicant: | LungLife AI, Inc. | |||
| Name of scheme: | 1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan | |||
| Number and class of securities originally admitted: | 1,356,139 common shares of US $0.0001 each | |||
| Date of admission: | 15 November 2021 | |||
| Period of return: | From: | 15 November 2022 | To: | 15 May 2023 |
| Balance of unallotted securities under scheme(s) from previous return: | 1. 475,583 2. 201,374 3. 673,990 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. NIL 2. NIL 3. NIL | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1. NIL 2. NIL 3. NIL | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1. 475,583 2. 201,374 3. 673,990 | |||
| Total number of securities in issue at the end of the period | 25,485,982 | |||
| Name of contact: | David Anderson, Chief Financial Officer |
| Telephone number of contact: | +44 (0)20 7933 8780 or lunglifeai@walbrookpr.com |
For the full announcement click HERE.
"*" indicates required fields
LungLife AI licensure/accreditation information posted here.